Last reviewed · How we verify
Pfizer COVID-19 mRNA vaccine
Pfizer COVID-19 mRNA vaccine is a mRNA vaccine Biologic drug developed by Methodist Health System. It is currently in Phase 2 development for COVID-19 prevention.
mRNA vaccine that encodes for the SARS-CoV-2 spike protein
mRNA vaccine that encodes for the SARS-CoV-2 spike protein Used for COVID-19 prevention.
At a glance
| Generic name | Pfizer COVID-19 mRNA vaccine |
|---|---|
| Sponsor | Methodist Health System |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
The Pfizer COVID-19 mRNA vaccine works by instructing cells to produce a piece of the SARS-CoV-2 spike protein, which triggers an immune response and provides protection against the virus.
Approved indications
- COVID-19 prevention
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. (PHASE3)
- COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
- Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients (PHASE2)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pfizer COVID-19 mRNA vaccine CI brief — competitive landscape report
- Pfizer COVID-19 mRNA vaccine updates RSS · CI watch RSS
- Methodist Health System portfolio CI
Frequently asked questions about Pfizer COVID-19 mRNA vaccine
What is Pfizer COVID-19 mRNA vaccine?
How does Pfizer COVID-19 mRNA vaccine work?
What is Pfizer COVID-19 mRNA vaccine used for?
Who makes Pfizer COVID-19 mRNA vaccine?
What drug class is Pfizer COVID-19 mRNA vaccine in?
What development phase is Pfizer COVID-19 mRNA vaccine in?
What are the side effects of Pfizer COVID-19 mRNA vaccine?
What does Pfizer COVID-19 mRNA vaccine target?
Related
- Drug class: All mRNA vaccine drugs
- Target: All drugs targeting SARS-CoV-2 spike protein
- Manufacturer: Methodist Health System — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for COVID-19 prevention
- Compare: Pfizer COVID-19 mRNA vaccine vs similar drugs
- Pricing: Pfizer COVID-19 mRNA vaccine cost, discount & access